Koninklijke Philips N.V.
Koninklijke Philips N.V. PHG Peers
See (PHG) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PHG | $24.12 | +0.82% | 22.3B | 80.27 | $0.30 | +3.68% |
| ABT | $134.71 | -1.96% | 232.6B | 17.38 | $7.69 | +1.71% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| BSX | $106.39 | +2.01% | 154.7B | 76.34 | $1.37 | N/A |
| SYK | $394.05 | +0.46% | 149.2B | 52.83 | $7.39 | +0.84% |
| MDT | $86.04 | +0.08% | 110.5B | 23.89 | $3.61 | +3.26% |
| EW | $77.60 | +0.81% | 45.3B | 31.88 | $2.42 | N/A |
| DXCM | $86.98 | +2.71% | 33.4B | 63.95 | $1.33 | N/A |
| STE | $239.96 | -0.17% | 23.5B | 38.65 | $6.17 | +0.96% |
| PODD | $312.24 | +1.96% | 21.8B | 55.83 | $5.55 | N/A |
Stock Comparison
PHG vs ABT Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, ABT has a market cap of 232.6B. Regarding current trading prices, PHG is priced at $24.12, while ABT trades at $134.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas ABT's P/E ratio is 17.38. In terms of profitability, PHG's ROE is +0.03%, compared to ABT's ROE of +0.31%. Regarding short-term risk, PHG is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs BSX-PA Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, PHG is priced at $24.12, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, PHG's ROE is +0.03%, compared to BSX-PA's ROE of +0.10%. Regarding short-term risk, PHG is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs BSX Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, BSX has a market cap of 154.7B. Regarding current trading prices, PHG is priced at $24.12, while BSX trades at $106.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas BSX's P/E ratio is 76.34. In terms of profitability, PHG's ROE is +0.03%, compared to BSX's ROE of +0.10%. Regarding short-term risk, PHG is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs SYK Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, SYK has a market cap of 149.2B. Regarding current trading prices, PHG is priced at $24.12, while SYK trades at $394.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas SYK's P/E ratio is 52.83. In terms of profitability, PHG's ROE is +0.03%, compared to SYK's ROE of +0.11%. Regarding short-term risk, PHG is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs MDT Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, MDT has a market cap of 110.5B. Regarding current trading prices, PHG is priced at $24.12, while MDT trades at $86.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas MDT's P/E ratio is 23.89. In terms of profitability, PHG's ROE is +0.03%, compared to MDT's ROE of +0.10%. Regarding short-term risk, PHG is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs EW Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, EW has a market cap of 45.3B. Regarding current trading prices, PHG is priced at $24.12, while EW trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas EW's P/E ratio is 31.88. In terms of profitability, PHG's ROE is +0.03%, compared to EW's ROE of +0.49%. Regarding short-term risk, PHG is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs DXCM Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, DXCM has a market cap of 33.4B. Regarding current trading prices, PHG is priced at $24.12, while DXCM trades at $86.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas DXCM's P/E ratio is 63.95. In terms of profitability, PHG's ROE is +0.03%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, PHG is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs STE Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, STE has a market cap of 23.5B. Regarding current trading prices, PHG is priced at $24.12, while STE trades at $239.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas STE's P/E ratio is 38.65. In terms of profitability, PHG's ROE is +0.03%, compared to STE's ROE of +0.09%. Regarding short-term risk, PHG is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs PODD Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, PODD has a market cap of 21.8B. Regarding current trading prices, PHG is priced at $24.12, while PODD trades at $312.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas PODD's P/E ratio is 55.83. In terms of profitability, PHG's ROE is +0.03%, compared to PODD's ROE of +0.35%. Regarding short-term risk, PHG is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs ZBH Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, ZBH has a market cap of 18.2B. Regarding current trading prices, PHG is priced at $24.12, while ZBH trades at $91.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas ZBH's P/E ratio is 20.39. In terms of profitability, PHG's ROE is +0.03%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, PHG is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs ABMD Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, PHG is priced at $24.12, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas ABMD's P/E ratio is 65.36. In terms of profitability, PHG's ROE is +0.03%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, PHG is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs ALGN Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, ALGN has a market cap of 13.6B. Regarding current trading prices, PHG is priced at $24.12, while ALGN trades at $188.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas ALGN's P/E ratio is 34.07. In terms of profitability, PHG's ROE is +0.03%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, PHG is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs SNN Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, SNN has a market cap of 13.2B. Regarding current trading prices, PHG is priced at $24.12, while SNN trades at $30.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas SNN's P/E ratio is 32.12. In terms of profitability, PHG's ROE is +0.03%, compared to SNN's ROE of +0.08%. Regarding short-term risk, PHG is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs SWAV Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, PHG is priced at $24.12, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas SWAV's P/E ratio is 78.76. In terms of profitability, PHG's ROE is +0.03%, compared to SWAV's ROE of +0.14%. Regarding short-term risk, PHG is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs PEN Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, PEN has a market cap of 9.8B. Regarding current trading prices, PHG is priced at $24.12, while PEN trades at $255.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas PEN's P/E ratio is 234.66. In terms of profitability, PHG's ROE is +0.03%, compared to PEN's ROE of +0.04%. Regarding short-term risk, PHG is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs GMED Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, GMED has a market cap of 8B. Regarding current trading prices, PHG is priced at $24.12, while GMED trades at $58.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas GMED's P/E ratio is 43.87. In terms of profitability, PHG's ROE is +0.03%, compared to GMED's ROE of +0.05%. Regarding short-term risk, PHG is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs BIO Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, BIO has a market cap of 6.6B. Regarding current trading prices, PHG is priced at $24.12, while BIO trades at $242.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas BIO's P/E ratio is -3.18. In terms of profitability, PHG's ROE is +0.03%, compared to BIO's ROE of -0.32%. Regarding short-term risk, PHG is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs BRKR Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, BRKR has a market cap of 6.4B. Regarding current trading prices, PHG is priced at $24.12, while BRKR trades at $41.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas BRKR's P/E ratio is 81.12. In terms of profitability, PHG's ROE is +0.03%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, PHG is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs BIO-B Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, BIO-B has a market cap of 6.3B. Regarding current trading prices, PHG is priced at $24.12, while BIO-B trades at $250.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas BIO-B's P/E ratio is -3.27. In terms of profitability, PHG's ROE is +0.03%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, PHG is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs GKOS Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, GKOS has a market cap of 5.8B. Regarding current trading prices, PHG is priced at $24.12, while GKOS trades at $103.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas GKOS's P/E ratio is -44.52. In terms of profitability, PHG's ROE is +0.03%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, PHG is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs IRTC Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, IRTC has a market cap of 4.9B. Regarding current trading prices, PHG is priced at $24.12, while IRTC trades at $153.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas IRTC's P/E ratio is -48.94. In terms of profitability, PHG's ROE is +0.03%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, PHG is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs NARI Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, PHG is priced at $24.12, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas NARI's P/E ratio is -59.24. In terms of profitability, PHG's ROE is +0.03%, compared to NARI's ROE of -0.18%. Regarding short-term risk, PHG is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs TMDX Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, TMDX has a market cap of 4.4B. Regarding current trading prices, PHG is priced at $24.12, while TMDX trades at $131.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas TMDX's P/E ratio is 91.59. In terms of profitability, PHG's ROE is +0.03%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, PHG is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs ITGR Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, PHG is priced at $24.12, while ITGR trades at $122.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas ITGR's P/E ratio is 56.67. In terms of profitability, PHG's ROE is +0.03%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, PHG is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs INSP Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, INSP has a market cap of 3.8B. Regarding current trading prices, PHG is priced at $24.12, while INSP trades at $130.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas INSP's P/E ratio is 59.19. In terms of profitability, PHG's ROE is +0.03%, compared to INSP's ROE of +0.10%. Regarding short-term risk, PHG is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs AXNX Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, PHG is priced at $24.12, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas AXNX's P/E ratio is -709.80. In terms of profitability, PHG's ROE is +0.03%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, PHG is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs PRCT Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, PRCT has a market cap of 3.2B. Regarding current trading prices, PHG is priced at $24.12, while PRCT trades at $57.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas PRCT's P/E ratio is -34.69. In terms of profitability, PHG's ROE is +0.03%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, PHG is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs LIVN Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, LIVN has a market cap of 2.5B. Regarding current trading prices, PHG is priced at $24.12, while LIVN trades at $45.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas LIVN's P/E ratio is -11.25. In terms of profitability, PHG's ROE is +0.03%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, PHG is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs NUVA Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, PHG is priced at $24.12, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas NUVA's P/E ratio is 75.00. In terms of profitability, PHG's ROE is +0.03%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, PHG is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs UFPT Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, UFPT has a market cap of 1.9B. Regarding current trading prices, PHG is priced at $24.12, while UFPT trades at $242.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas UFPT's P/E ratio is 30.32. In terms of profitability, PHG's ROE is +0.03%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, PHG is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs CNMD Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, CNMD has a market cap of 1.6B. Regarding current trading prices, PHG is priced at $24.12, while CNMD trades at $52.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas CNMD's P/E ratio is 13.73. In terms of profitability, PHG's ROE is +0.03%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, PHG is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs ATEC Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, PHG is priced at $24.12, while ATEC trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas ATEC's P/E ratio is -9.56. In terms of profitability, PHG's ROE is +0.03%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, PHG is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs HSKA Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, PHG is priced at $24.12, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas HSKA's P/E ratio is -62.49. In terms of profitability, PHG's ROE is +0.03%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, PHG is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs AORT Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, PHG is priced at $24.12, while AORT trades at $30.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas AORT's P/E ratio is -60.06. In terms of profitability, PHG's ROE is +0.03%, compared to AORT's ROE of -0.07%. Regarding short-term risk, PHG is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs TNDM Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, PHG is priced at $24.12, while TNDM trades at $19.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas TNDM's P/E ratio is -6.85. In terms of profitability, PHG's ROE is +0.03%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, PHG is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs AHCO Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, PHG is priced at $24.12, while AHCO trades at $9.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas AHCO's P/E ratio is 16.24. In terms of profitability, PHG's ROE is +0.03%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, PHG is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs SSII Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, SSII has a market cap of 1.3B. Regarding current trading prices, PHG is priced at $24.12, while SSII trades at $6.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas SSII's P/E ratio is -81.75. In terms of profitability, PHG's ROE is +0.03%, compared to SSII's ROE of -1.33%. Regarding short-term risk, PHG is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs ESTA Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, ESTA has a market cap of 1.2B. Regarding current trading prices, PHG is priced at $24.12, while ESTA trades at $41.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas ESTA's P/E ratio is -13.09. In terms of profitability, PHG's ROE is +0.03%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, PHG is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs SILK Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, PHG is priced at $24.12, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas SILK's P/E ratio is -18.96. In terms of profitability, PHG's ROE is +0.03%, compared to SILK's ROE of -0.29%. Regarding short-term risk, PHG is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs FNA Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, PHG is priced at $24.12, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas FNA's P/E ratio is -19.83. In terms of profitability, PHG's ROE is +0.03%, compared to FNA's ROE of -0.36%. Regarding short-term risk, PHG is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs INMD Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, INMD has a market cap of 978.7M. Regarding current trading prices, PHG is priced at $24.12, while INMD trades at $14.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas INMD's P/E ratio is 6.31. In terms of profitability, PHG's ROE is +0.03%, compared to INMD's ROE of +0.25%. Regarding short-term risk, PHG is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs IART Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, IART has a market cap of 948.9M. Regarding current trading prices, PHG is priced at $24.12, while IART trades at $12.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas IART's P/E ratio is -32.13. In terms of profitability, PHG's ROE is +0.03%, compared to IART's ROE of -0.03%. Regarding short-term risk, PHG is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs CSII Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, PHG is priced at $24.12, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas CSII's P/E ratio is -20.83. In terms of profitability, PHG's ROE is +0.03%, compared to CSII's ROE of -0.14%. Regarding short-term risk, PHG is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs SIBN Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, SIBN has a market cap of 770.9M. Regarding current trading prices, PHG is priced at $24.12, while SIBN trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas SIBN's P/E ratio is -28.71. In terms of profitability, PHG's ROE is +0.03%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, PHG is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs IRMD Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, IRMD has a market cap of 770.7M. Regarding current trading prices, PHG is priced at $24.12, while IRMD trades at $60.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas IRMD's P/E ratio is 39.11. In terms of profitability, PHG's ROE is +0.03%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, PHG is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs CRY Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, PHG is priced at $24.12, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas CRY's P/E ratio is 425.71. In terms of profitability, PHG's ROE is +0.03%, compared to CRY's ROE of -0.07%. Regarding short-term risk, PHG is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs CBLL Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, CBLL has a market cap of 697.2M. Regarding current trading prices, PHG is priced at $24.12, while CBLL trades at $19.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas CBLL's P/E ratio is -15.43. In terms of profitability, PHG's ROE is +0.03%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, PHG is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs APEN Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, PHG is priced at $24.12, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas APEN's P/E ratio is -9.43. In terms of profitability, PHG's ROE is +0.03%, compared to APEN's ROE of -0.85%. Regarding short-term risk, PHG is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs BFLY-WT Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, BFLY-WT has a market cap of 578M. Regarding current trading prices, PHG is priced at $24.12, while BFLY-WT trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, PHG's ROE is +0.03%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, PHG is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs AVNS Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, AVNS has a market cap of 562.3M. Regarding current trading prices, PHG is priced at $24.12, while AVNS trades at $12.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas AVNS's P/E ratio is -1.47. In terms of profitability, PHG's ROE is +0.03%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, PHG is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs KIDS Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, KIDS has a market cap of 539.2M. Regarding current trading prices, PHG is priced at $24.12, while KIDS trades at $21.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas KIDS's P/E ratio is -12.37. In terms of profitability, PHG's ROE is +0.03%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, PHG is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs RXST Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, RXST has a market cap of 537.6M. Regarding current trading prices, PHG is priced at $24.12, while RXST trades at $13.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas RXST's P/E ratio is -20.05. In terms of profitability, PHG's ROE is +0.03%, compared to RXST's ROE of -0.10%. Regarding short-term risk, PHG is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs BFLY Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, BFLY has a market cap of 499.5M. Regarding current trading prices, PHG is priced at $24.12, while BFLY trades at $1.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas BFLY's P/E ratio is -6.73. In terms of profitability, PHG's ROE is +0.03%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, PHG is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs AXGN Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, AXGN has a market cap of 476.4M. Regarding current trading prices, PHG is priced at $24.12, while AXGN trades at $10.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas AXGN's P/E ratio is -65.37. In terms of profitability, PHG's ROE is +0.03%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, PHG is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs CTKB Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, CTKB has a market cap of 449.6M. Regarding current trading prices, PHG is priced at $24.12, while CTKB trades at $3.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas CTKB's P/E ratio is -39.44. In terms of profitability, PHG's ROE is +0.03%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, PHG is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs BVS Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, BVS has a market cap of 441.9M. Regarding current trading prices, PHG is priced at $24.12, while BVS trades at $6.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas BVS's P/E ratio is -13.87. In terms of profitability, PHG's ROE is +0.03%, compared to BVS's ROE of -0.21%. Regarding short-term risk, PHG is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs SMLR Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, SMLR has a market cap of 432.6M. Regarding current trading prices, PHG is priced at $24.12, while SMLR trades at $39.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas SMLR's P/E ratio is -16.23. In terms of profitability, PHG's ROE is +0.03%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, PHG is less volatile compared to SMLR. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs OFIX Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, OFIX has a market cap of 432.6M. Regarding current trading prices, PHG is priced at $24.12, while OFIX trades at $11.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas OFIX's P/E ratio is -2.98. In terms of profitability, PHG's ROE is +0.03%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, PHG is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs SRDX Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, SRDX has a market cap of 416M. Regarding current trading prices, PHG is priced at $24.12, while SRDX trades at $28.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas SRDX's P/E ratio is -20.78. In terms of profitability, PHG's ROE is +0.03%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, PHG is less volatile compared to SRDX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs PACB Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, PACB has a market cap of 387.1M. Regarding current trading prices, PHG is priced at $24.12, while PACB trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas PACB's P/E ratio is -0.47. In terms of profitability, PHG's ROE is +0.03%, compared to PACB's ROE of -1.70%. Regarding short-term risk, PHG is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs SENS Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, SENS has a market cap of 377.3M. Regarding current trading prices, PHG is priced at $24.12, while SENS trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas SENS's P/E ratio is -4.55. In terms of profitability, PHG's ROE is +0.03%, compared to SENS's ROE of -7.46%. Regarding short-term risk, PHG is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs NPCE Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, NPCE has a market cap of 358.8M. Regarding current trading prices, PHG is priced at $24.12, while NPCE trades at $10.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas NPCE's P/E ratio is -13.34. In terms of profitability, PHG's ROE is +0.03%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, PHG is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs OM Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, OM has a market cap of 356.7M. Regarding current trading prices, PHG is priced at $24.12, while OM trades at $19.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas OM's P/E ratio is -0.70. In terms of profitability, PHG's ROE is +0.03%, compared to OM's ROE of -1.45%. Regarding short-term risk, PHG is less volatile compared to OM. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs VREX Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, VREX has a market cap of 354.4M. Regarding current trading prices, PHG is priced at $24.12, while VREX trades at $8.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas VREX's P/E ratio is -8.29. In terms of profitability, PHG's ROE is +0.03%, compared to VREX's ROE of -0.08%. Regarding short-term risk, PHG is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs TMCI Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, TMCI has a market cap of 351.6M. Regarding current trading prices, PHG is priced at $24.12, while TMCI trades at $5.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas TMCI's P/E ratio is -6.58. In terms of profitability, PHG's ROE is +0.03%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, PHG is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs NNOX Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, NNOX has a market cap of 343M. Regarding current trading prices, PHG is priced at $24.12, while NNOX trades at $5.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas NNOX's P/E ratio is -5.91. In terms of profitability, PHG's ROE is +0.03%, compared to NNOX's ROE of -0.31%. Regarding short-term risk, PHG is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs CLPT Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, CLPT has a market cap of 339.7M. Regarding current trading prices, PHG is priced at $24.12, while CLPT trades at $11.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas CLPT's P/E ratio is -15.82. In terms of profitability, PHG's ROE is +0.03%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, PHG is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs SNWV Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, SNWV has a market cap of 282.7M. Regarding current trading prices, PHG is priced at $24.12, while SNWV trades at $31.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas SNWV's P/E ratio is -5.30. In terms of profitability, PHG's ROE is +0.03%, compared to SNWV's ROE of +1.00%. Regarding short-term risk, PHG is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs VMD Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, VMD has a market cap of 273.1M. Regarding current trading prices, PHG is priced at $24.12, while VMD trades at $7.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas VMD's P/E ratio is 23.03. In terms of profitability, PHG's ROE is +0.03%, compared to VMD's ROE of +0.10%. Regarding short-term risk, PHG is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs CATX Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, CATX has a market cap of 268M. Regarding current trading prices, PHG is priced at $24.12, while CATX trades at $3.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas CATX's P/E ratio is -2.93. In terms of profitability, PHG's ROE is +0.03%, compared to CATX's ROE of -0.27%. Regarding short-term risk, PHG is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs CERS Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, CERS has a market cap of 260M. Regarding current trading prices, PHG is priced at $24.12, while CERS trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas CERS's P/E ratio is -13.60. In terms of profitability, PHG's ROE is +0.03%, compared to CERS's ROE of -0.35%. Regarding short-term risk, PHG is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs QTRX Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, QTRX has a market cap of 255.3M. Regarding current trading prices, PHG is priced at $24.12, while QTRX trades at $6.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas QTRX's P/E ratio is -5.30. In terms of profitability, PHG's ROE is +0.03%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, PHG is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs ZIMV Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, ZIMV has a market cap of 251.3M. Regarding current trading prices, PHG is priced at $24.12, while ZIMV trades at $9.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas ZIMV's P/E ratio is -10.00. In terms of profitability, PHG's ROE is +0.03%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, PHG is less volatile compared to ZIMV. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs PTHL Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, PTHL has a market cap of 249.2M. Regarding current trading prices, PHG is priced at $24.12, while PTHL trades at $17.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas PTHL's P/E ratio is -349.80. In terms of profitability, PHG's ROE is +0.03%, compared to PTHL's ROE of -0.30%. Regarding short-term risk, PHG is less volatile compared to PTHL. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs BWAY Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, BWAY has a market cap of 245.8M. Regarding current trading prices, PHG is priced at $24.12, while BWAY trades at $13.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas BWAY's P/E ratio is 59.14. In terms of profitability, PHG's ROE is +0.03%, compared to BWAY's ROE of +0.06%. Regarding short-term risk, PHG is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs MXCT Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, MXCT has a market cap of 244.5M. Regarding current trading prices, PHG is priced at $24.12, while MXCT trades at $2.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas MXCT's P/E ratio is -5.75. In terms of profitability, PHG's ROE is +0.03%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, PHG is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs MASS Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, MASS has a market cap of 241.7M. Regarding current trading prices, PHG is priced at $24.12, while MASS trades at $6.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas MASS's P/E ratio is -3.04. In terms of profitability, PHG's ROE is +0.03%, compared to MASS's ROE of -0.13%. Regarding short-term risk, PHG is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs TCMD Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, TCMD has a market cap of 238.1M. Regarding current trading prices, PHG is priced at $24.12, while TCMD trades at $10.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas TCMD's P/E ratio is 15.52. In terms of profitability, PHG's ROE is +0.03%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, PHG is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs BSGM Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, BSGM has a market cap of 231.5M. Regarding current trading prices, PHG is priced at $24.12, while BSGM trades at $7.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas BSGM's P/E ratio is -16.00. In terms of profitability, PHG's ROE is +0.03%, compared to BSGM's ROE of -35.30%. Regarding short-term risk, PHG is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs NVRO Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, PHG is priced at $24.12, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas NVRO's P/E ratio is -1.91. In terms of profitability, PHG's ROE is +0.03%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, PHG is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs SGHT Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, SGHT has a market cap of 219.7M. Regarding current trading prices, PHG is priced at $24.12, while SGHT trades at $4.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas SGHT's P/E ratio is -4.34. In terms of profitability, PHG's ROE is +0.03%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, PHG is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs EYES Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, PHG is priced at $24.12, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas EYES's P/E ratio is N/A. In terms of profitability, PHG's ROE is +0.03%, compared to EYES's ROE of -0.26%. Regarding short-term risk, PHG is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs INGN Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, INGN has a market cap of 193.5M. Regarding current trading prices, PHG is priced at $24.12, while INGN trades at $7.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas INGN's P/E ratio is -6.26. In terms of profitability, PHG's ROE is +0.03%, compared to INGN's ROE of -0.15%. Regarding short-term risk, PHG is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs TLSI Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, TLSI has a market cap of 192.5M. Regarding current trading prices, PHG is priced at $24.12, while TLSI trades at $5.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas TLSI's P/E ratio is -4.61. In terms of profitability, PHG's ROE is +0.03%, compared to TLSI's ROE of +1.04%. Regarding short-term risk, PHG is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs PROF Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, PROF has a market cap of 184.2M. Regarding current trading prices, PHG is priced at $24.12, while PROF trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas PROF's P/E ratio is -5.07. In terms of profitability, PHG's ROE is +0.03%, compared to PROF's ROE of -0.70%. Regarding short-term risk, PHG is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs ELMD Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, ELMD has a market cap of 181.8M. Regarding current trading prices, PHG is priced at $24.12, while ELMD trades at $21.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas ELMD's P/E ratio is 27.44. In terms of profitability, PHG's ROE is +0.03%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, PHG is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs BDMD Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, BDMD has a market cap of 162M. Regarding current trading prices, PHG is priced at $24.12, while BDMD trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas BDMD's P/E ratio is 9.25. In terms of profitability, PHG's ROE is +0.03%, compared to BDMD's ROE of +0.12%. Regarding short-term risk, PHG is less volatile compared to BDMD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs ANIK Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, ANIK has a market cap of 155.3M. Regarding current trading prices, PHG is priced at $24.12, while ANIK trades at $10.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas ANIK's P/E ratio is -14.44. In terms of profitability, PHG's ROE is +0.03%, compared to ANIK's ROE of -0.33%. Regarding short-term risk, PHG is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs CVRX Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, CVRX has a market cap of 152.8M. Regarding current trading prices, PHG is priced at $24.12, while CVRX trades at $5.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas CVRX's P/E ratio is -2.74. In terms of profitability, PHG's ROE is +0.03%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, PHG is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs RPID Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, RPID has a market cap of 152.5M. Regarding current trading prices, PHG is priced at $24.12, while RPID trades at $3.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas RPID's P/E ratio is -3.38. In terms of profitability, PHG's ROE is +0.03%, compared to RPID's ROE of -0.56%. Regarding short-term risk, PHG is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs LNSR Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, LNSR has a market cap of 149.4M. Regarding current trading prices, PHG is priced at $24.12, while LNSR trades at $12.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas LNSR's P/E ratio is -2.58. In terms of profitability, PHG's ROE is +0.03%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, PHG is less volatile compared to LNSR. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs AVR Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, AVR has a market cap of 149.2M. Regarding current trading prices, PHG is priced at $24.12, while AVR trades at $4.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas AVR's P/E ratio is -1.15. In terms of profitability, PHG's ROE is +0.03%, compared to AVR's ROE of -2.92%. Regarding short-term risk, PHG is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs RCEL Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, RCEL has a market cap of 135.1M. Regarding current trading prices, PHG is priced at $24.12, while RCEL trades at $5.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas RCEL's P/E ratio is -2.33. In terms of profitability, PHG's ROE is +0.03%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, PHG is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs LUCD Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, LUCD has a market cap of 128.8M. Regarding current trading prices, PHG is priced at $24.12, while LUCD trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas LUCD's P/E ratio is -1.02. In terms of profitability, PHG's ROE is +0.03%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, PHG is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs OWLT Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, OWLT has a market cap of 127.1M. Regarding current trading prices, PHG is priced at $24.12, while OWLT trades at $7.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas OWLT's P/E ratio is -4.78. In terms of profitability, PHG's ROE is +0.03%, compared to OWLT's ROE of +1.25%. Regarding short-term risk, PHG is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs ICAD Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, ICAD has a market cap of 105.9M. Regarding current trading prices, PHG is priced at $24.12, while ICAD trades at $3.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas ICAD's P/E ratio is -20.29. In terms of profitability, PHG's ROE is +0.03%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, PHG is less volatile compared to ICAD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs LUNG Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, LUNG has a market cap of 104.3M. Regarding current trading prices, PHG is priced at $24.12, while LUNG trades at $2.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas LUNG's P/E ratio is -1.80. In terms of profitability, PHG's ROE is +0.03%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, PHG is less volatile compared to LUNG. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs MGRM Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, MGRM has a market cap of 102.4M. Regarding current trading prices, PHG is priced at $24.12, while MGRM trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas MGRM's P/E ratio is -5.74. In terms of profitability, PHG's ROE is +0.03%, compared to MGRM's ROE of -1.26%. Regarding short-term risk, PHG is less volatile compared to MGRM. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs HJLI Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 22.3B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, PHG is priced at $24.12, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 80.27, whereas HJLI's P/E ratio is N/A. In terms of profitability, PHG's ROE is +0.03%, compared to HJLI's ROE of -0.51%. Regarding short-term risk, PHG is less volatile compared to HJLI. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.